Tango Therapeutics Inc (TNGX)

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Tango Therapeutics Appoints Robert Azelby to Board of Directors

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage...

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tango Therapeutics Announces Proposed $500 Million Public Offering

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage...

Form 8-K - Current report

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat...

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that...

Form 8-K - Current report